Related references
Note: Only part of the references are listed.Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity
Ole Audun Werner Haabeth et al.
CANCER RESEARCH (2019)
A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma
So Young Yoo et al.
CANCERS (2019)
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Zong Sheng Guo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Kathy Matuszewska et al.
CLINICAL CANCER RESEARCH (2019)
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Sylvain Simon et al.
ONCOIMMUNOLOGY (2018)
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
Chao-Qun Liu et al.
BRITISH JOURNAL OF CANCER (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Ibrahim Ragab Eissa et al.
CANCERS (2018)
Local delivery of a cancer-favoring oncolytic vaccinia virus via poly (lactic-co-glycolic acid) nanofiber for theranostic purposes
Narayanasamy Badrinath et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Christopher J. LaRocca et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau et al.
NATURE COMMUNICATIONS (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma
So Young Yoo et al.
ONCOTARGET (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Jan Willem Kleinovink et al.
ONCOIMMUNOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy
Sarita M. Fernandez-Poma et al.
CANCER RESEARCH (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
Laetitia Fend et al.
ONCOIMMUNOLOGY (2016)
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
Zuqiang Liu et al.
ONCOIMMUNOLOGY (2016)
Viruses as nanomedicine for cancer
Narayanasamy Badrinath et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer
So Young Yoo et al.
ONCOTARGET (2016)
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Juan J. Rojas et al.
CLINICAL CANCER RESEARCH (2015)
Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
Meng Xu et al.
JOURNAL OF IMMUNOLOGY (2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park et al.
MOLECULAR THERAPY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk et al.
CANCER RESEARCH (2015)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
B7 family checkpoint regulators in immune regulation and disease
Sabrina Ceeraz et al.
TRENDS IN IMMUNOLOGY (2013)
The tumor microenvironment at a glance
Frances R. Balkwill et al.
JOURNAL OF CELL SCIENCE (2012)
Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells
S. Peter Bak et al.
JOURNAL OF IMMUNOLOGY (2012)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Impact of tumor microenvironment on oncolytic viral therapy
Jeffrey Wojton et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Costimulatory and coinhibitory receptors in anti-tumor immunity
Gregory Driessens et al.
IMMUNOLOGICAL REVIEWS (2009)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J. H. Kim et al.
MOLECULAR THERAPY (2006)
Fighting cancer with vaccinia virus: Teaching new tricks to an old dog
YQ Shen et al.
MOLECULAR THERAPY (2005)
Share Paper
